Schrodinger Forecasts $350 Million 2026 Revenue, Stock Jumps 14%

Schrodinger Inc (SDGR) announced its financial outlook for 2026 on 21 June 2026, projecting annual revenue of $350 million. The forecast represents a 40% increase over the company's expected 2025 revenue of $250 million. This forward guidance triggered a 14% single-day surge in the company's share price, closing at $42.50. The update was provided by company executives during a mid-year business review detailed in a filing with the Securities and Exchange Commission.

Context — why this matters now

The 2026 revenue projection is the most aggressive growth target Schrodinger has issued since its 2020 initial public offering. In February 2023, the company projected 2025 revenue of $200 million, a target it later raised to $250 million in November 2025. The current macro backdrop for biotech is defined by the iShares Biotechnology ETF (IBB) trading near a two-year high and the Federal Funds Target Rate at 3.75%. The catalyst for the raised outlook is the maturation of Schrodinger's collaborative drug discovery pipeline beyond its core software licensing business. Several programs with partners like Bristol Myers Squibb and Eli Lilly have advanced into late-stage preclinical trials, unlocking milestone payments and future royalty stakes.

Data — what the numbers show

The $350 million 2026 revenue target breaks down into two primary segments. Software revenue is projected to reach $180 million, up from an estimated $155 million in 2025. Collaborative drug discovery revenue is forecast to hit $170 million, more than double its 2025 estimated $95 million. The company's market capitalization increased by approximately $550 million following the announcement, reaching $4.5 billion. Schrodinger's stock performance of +14% on the news significantly outpaced the Nasdaq Biotechnology Index's (NBI) flat movement for the same session.

Metric	2025 (Est.)	2026 (Proj.)	Change
Total Revenue	$250M	$350M	+40%
Software Revenue	$155M	$180M	+16%
Collaboration Revenue	$95M	$170M	+79%

The growth in collaboration revenue is central to the investment thesis. This segment's contribution to total revenue is projected to rise from 38% in 2025 to 49% in 2026, nearing parity with software sales.

Analysis — what it means for markets / sectors / tickers

The outlook validates the platform-based biotech model, where computational tools enable internal asset creation. Primary beneficiaries include peers like Recursion Pharmaceuticals (RXRX) and Relay Therapeutics (RLAY), whose shares rose 5% and 4% respectively in sympathy trading. Companies reliant on traditional contract research, such as Charles River Laboratories (CRL), may face incremental pressure as drug developers shift budget towards tech-enabled discovery partnerships. A key risk is the binary nature of clinical milestones; a Phase III failure in a key partnered program could erase future royalty projections and contract the revenue multiple. Institutional flow data indicates net buying in SDGR call options for July and September expiries, with open interest increasing by 35%. Short interest remains elevated at 18% of float, setting the stage for potential volatility around upcoming clinical catalysts.

Outlook — what to watch next

The next major catalyst is the second-quarter 2026 earnings report, scheduled for 5 August 2026, which will provide an update on year-to-date performance against the new targets. Investors will monitor the progression of SDGR-001, a proprietary oncology program, with Phase I data expected by the end of Q3 2026. Key technical levels for the stock include immediate support at $38.50, the pre-announcement closing price, and resistance near $48, its 52-week high from January 2026. If the 10-year Treasury yield breaks above 4.5%, it could pressure valuation multiples across growth-oriented biotech stocks, including Schrodinger. Success in any one of the three lead collaborative programs entering Phase II trials in 2027 would likely trigger further upward revisions.

Frequently Asked Questions

What does Schrodinger's revenue mix shift mean for its profit margins?

Schrodinger's collaborative drug discovery revenue carries higher gross margins than its software licensing over the long term, as milestone payments are predominantly profit. However, the company incurs significant upfront research and development costs to advance these programs, which pressures near-term operating margins. The 2026 projection implies the company is investing for future royalty streams, meaning net profitability may remain muted until key assets successfully transition to late-stage clinical trials or commercialization.

How does Schrodinger's business model compare to a traditional biotech like Moderna?

Unlike Moderna, which fully internalizes drug development from discovery through commercialization, Schrodinger operates a hybrid platform. It monetizes its software tools via licenses to other pharmaceutical companies while also using those tools to discover drugs in partnership, sharing costs, risks, and rewards. This model aims to generate more predictable software revenue while offering leveraged upside through royalties, a contrast to the high-capital, binary outcome model of a pure-play drug developer.

Is Schrodinger's technology used outside of drug discovery?

Yes, while life sciences is its primary market, Schrodinger's computational physics and machine learning platforms have applications in materials science. The company has partnerships in semiconductors and energy storage, such as a 2025 agreement with a major chipmaker to discover new organic materials for advanced packaging. This diversifies its revenue base and demonstrates the broader applicability of its underlying science beyond biologics and small molecules.

Bottom Line

Schrodinger's 2026 outlook signals its successful transition from a software vendor to a high-growth, asset-creating biotech platform.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.